Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages

  Waidmann, O ^a   Bihrer, V ^a   Pleli, T ^a   Farnik, H ^a   Berger, A ^a   Zeuzem, S ^a   Kronenberger, B ^a   Piiper, A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

HBs antigen; HBV carrier; HBV DNA; hepatitis B; microRNA 122

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; MICRORNA; MICRORNA 122; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ADULT; BIOLOGICAL MARKERS; BIOPSY; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; LIVER; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SERUM;

EID: 84855826136     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01536.x     Document Type: Article

References (25)

1. Dienstag JL,. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
2. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
3. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55: 61-68.
4. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
5. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
6. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
7. Wong SN, Lok AS,. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12. (Pubitemid 43063836)
8. Ambros V,. The functions of animal microRNAs. Nature 2004; 431: 350-355. (Pubitemid 39265675)
9. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
10. Kloosterman WP, Plasterk RH,. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450. (Pubitemid 44430905)
11. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
12. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010; 285: 17442-17452.
13. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739. (Pubitemid 34455427)
14. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
15. Qiu L, Fan H, Jin W, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010; 398: 771-777.
16. Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56: 1830-1838.
17. Xu J, Wu C, Che X, et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142.
18. Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106: 1663-1669.
19. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
20. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS,. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011; 57: 84-91.
21. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008; 57: 500-506. (Pubitemid 351442534)
22. Baumert TF, Thimme R, von Weizsäcker F,. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90. (Pubitemid 46165465)
23. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55: 1977-1983.
24. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P,. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581. (Pubitemid 41266486)
25. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL,. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008; 375: 315-320.